Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18488625 | 0.78 | DRD2 (0.47) | DRD2DRD3KDM1A | |
| SCHEMBL915459 | 0.75 | DRD2 (0.39) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2762077 | 0.75 | DRD2 (0.39) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2762076 | 0.75 | DRD2 (0.39) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL17483552 | 0.74 | DRD2 (0.39) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6108618 | 0.74 | — | — | |
| SCHEMBL12371117 | 0.74 | HTR2A (0.42) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL28948610 | 0.74 | FUCA1 (0.41) | DRD2DRD3KDM1A | |
| SCHEMBL6108615 | 0.74 | — | — | |
| SCHEMBL760251 | 0.74 | HTR2A (0.42) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR INC. | 2019-06-27 | — | — | US | disclosed |
| US-10273244-B2 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | INDIVIOR UK LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10273244-B2 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | INDIVIOR UK LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| EP-3331886-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | Indivior UK Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021920-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017021920-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| EP-1948605-A2 | MODULATORS OF THE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007061741-A2 | MODULATORS OF THE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885KDM1A 2323/4885 |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885KDM1A 2160/4885 |
| US-10273244-B2 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | DRD3, DRD2, OPRD1 | DRD2 2/4885DRD3 1/4885KDM1A 1739/4885 |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885KDM1A 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.